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http://dx.doi.org/10.1016/j.stemcr.2016.03.006SUMMARYHematopoietic cells emerge from hemogenic endothelium in the developing embryo. Mechanisms behind human hematopoietic stem
and progenitor cell development remain unclear. Using a human pluripotent stem cell differentiation model, we report that cyclic AMP
(cAMP) induction dramatically increases HSC-like cell frequencies. We show that hematopoietic cell generation requires cAMP signaling
through the Exchange proteins activated by cAMP (cAMP-Epac) axis; Epac signaling inhibition decreased both hemogenic and non-
hemogenic endothelium, and abrogated hematopoietic cell generation. Furthermore, in hematopoietic progenitor and stem-like cells,
cAMP induction mitigated oxidative stress, created a redox-state balance, and enhanced C-X-C chemokine receptor type 4 (CXCR4)
expression, benefiting the maintenance of these primitive cells. Collectively, our study provides insights and mechanistic details on
the previously unrecognized role of cAMP signaling in regulatinghumanhematopoietic development. These findings advance themech-
anistic understanding of hematopoietic development toward the development of transplantable human hematopoietic cells for thera-
peutic needs.INTRODUCTION
Hematopoietic stem cells (HSCs) replenish the hematopoi-
etic system throughout the lifetime of an individual, and
can be transplanted into patients to treat malignant and
non-malignant blood disorders. The need to develop an
alternative source of HSCs to matched adult donors, such
as HSCs generated in vitro from pluripotent stem cells,
requires increased understanding of the mechanisms of
HSC development. During development, the first he-
matopoietic cells emerge from hemogenic endothelium
in the embryonic aorta-gonad-mesonephros (AGM) region
through endothelial-to-hematopoietic transition (EHT)
(Zovein et al., 2008). The concurrence of neural crest
stem cells in the AGM region coincides with the time of
HSC emergence, suggesting a link between neural crest/cat-
echolamines and hematopoietic development (Nagoshi
et al., 2008). Recently, catecholamine signaling was re-
ported to regulate HSC emergence in the AGM region, as
the deletion of GATA binding protein 3 (GATA3), a crucial
regulator of catecholamine production, compromised HSC
development, which could be rescued with administration
of catecholamine derivatives (Fitch et al., 2012). However,
the mechanism of catecholamine signaling, through its
second messenger, cyclic AMP (30-50-cyclic AMP; cAMP)
and its downstream signaling pathways have not been
critically evaluated in the context of hematopoietic
development.
In the adult hematopoietic system, a situation parallel
to the hematopoietic developmental context exists. Cate-
cholamines and sympathoadrenergic innervation (Afan692 Stem Cell Reports j Vol. 6 j 692–703 j May 10, 2016 j ª 2016 The Autho
This is an open access article under the CC BY-NC-ND license (http://creativet al., 1997; Mendez-Ferrer et al., 2010) of the bonemarrow
(BM) niche regulates HSC mobilization and migration (Ka-
tayama et al., 2006; Lucas et al., 2013; Mendez-Ferrer et al.,
2008) of catecholamine receptor-expressing hematopoietic
stem and progenitor cells (Heidt et al., 2014; Spiegel et al.,
2007). Together, these studies during developmental he-
matopoiesis and adult hematopoiesis provide evidence
for neural regulation of hematopoietic cells and establish
catecholamine-mediated signaling as a key component of
the hematopoietic program.
Activation of specific G-protein-coupled receptors by
catecholamines, as well as neurotransmitters, growth fac-
tors, and hormones, activate the cAMP-signaling pathway
(Beavo and Brunton, 2002; Sutherland and Rall, 1958), fol-
lowed by cell-type dependent responsesmediated by cAMP
effectors protein kinase A (PKA) (Walsh et al., 1968) and
Exchange proteins activated by cAMP (Epac) (de Rooij
et al., 1998). Epac have been shown to modulate endothe-
lial cell remodeling, enhance endothelial cell adhesion,
and regulate the integrity of endothelial cell junctions
(Cullere et al., 2005; Fukuhara et al., 2005; Kooistra et al.,
2005). However, the role of Epac signaling in hemogenic
endothelium is unknown.
cAMP-mediated regulation of adult hematopoiesis is
emphasized in studies showing that cAMP increases C-X-C
chemokine receptor type 4 (CXCR4) expression and
motility of hematopoietic progenitors (Goichberg et al.,
2006), HSCs fromGsa-deficientmice do not engraft (Adams
et al., 2009), and Gsa-deficient osteocytes alter the BM
niche, leading to defective hematopoiesis (Fulzele et al.,
2013). In human hematopoietic cells, prostaglandin E2rs
ecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. cAMP Induction Increases HSC-like Frequency during hPSC-to-Hematopoietic Differentiation
(A) Conditions and timeline applied to differentiate hPSCs toward mesoderm commitment and hematopoietic differentiation.
(B) Flow cytometric analysis of hematopoietic cells at day 14 of differentiation. Representative flow cytometry plots (biexponential axis)
of cells cultured in control medium (MesoTotal), and cells treated with forskolin, IBMX, or forskolin + IBMX are shown.
(C) Percentage of the hematopoietic surface phenotypes indicated in (B). Data represent mean ± SEM of three independent experiments.
Statistical analysis was performed using the t test. Significance compared with the control setting: *p < 0.05, ***p < 0.001; n.s., not
significant.
(D) Frequency of the putative HSC-like cells (in viable fraction). Data represent mean ± SEM of three independent experiments. Statistical
analysis was performed using the t test. Significance compared with the control setting: *p < 0.05; n.s., not significant.
(E) Total CFU numbers after 12-day CFU assay of differentiated hematopoietic cells treated with forskolin, IBMX, and forskolin + IBMX. The
CFU distribution of three independent experiments is shown as mean ± SEM CFU-G (granulocyte), CFU-M (macrophage), CFU-E (erythroid),
CFU-GM (granulocyte/macrophage). Statistical analysis was performed using the t test. Significance compared with the control setting:
*p < 0.05, **p < 0.01, ***p < 0.001.
(legend continued on next page)
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(PGE2)-mediated cAMP activation enhances human cord
blood engraftment (Cutler et al., 2013; Goessling et al.,
2011). Recently, cAMPwas shownto regulatehematopoietic
emergence and homing in studies where cAMPwas upregu-
latedby adenosine in zebrafish andmouse (Jing et al., 2015),
PGE2 in zebrafish and mouse (Diaz et al., 2015; Goessling
et al., 2009; Hoggatt et al., 2009; North et al., 2007), and
shear stress in murine AGM (Kim et al., 2015). However,
the role and mechanism of cAMP signaling, as mediated
throughPKAandEpac, in regulatinghumandevelopmental
hematopoiesis has not been adequately studied, and no
studyhasbeenperformedon the role of cAMP in thehuman
hematopoietic developmental context.
Human pluripotent stem cells (hPSCs), including hu-
man embryonic stem cells (Thomson et al., 1998) and
induced pluripotent stem cells (iPSCs) (Takahashi et al.,
2007), provide an ideal in vitro model to recapitulate
human hematopoietic development. We have shown
that hPSC-derived HSC-like cells possess lymphoid and
myeloid differentiation ability, a key feature of HSCs
(Ronn et al., 2015). Recent studies have functionally
demonstrated an endothelial precursor to blood (hemo-
genic endothelium) from hPSC differentiation cultures
(Ditadi et al., 2015; Slukvin, 2013), further establishing
hPSCs as a suitable model to study human hematopoi-
etic cell development. However, the signals regulating
hemogenic endothelium and newly emergent HSCs in
the human developmental context remain undefined.
In addition, for functional transplantable HSCs it is vital
to reduce reactive oxygen species (ROS) and oxidative
stress, as reduced ROS is crucial for HSC functionality
(Ito et al., 2006; Jang and Sharkis, 2007; Yahata et al.,
2011).
As cAMP-mediated regulation of human hematopoietic
cell emergence remains elusive, we set out to investigate
the role of cAMP signaling in the development of he-
matopoietic progenitors from hPSCs. Here, we demon-
strate that cAMP induction during hPSC-to-hematopoiet-
ic differentiation increases the frequency of cells with
HSC-like surface phenotype and increases the colony-
forming unit (CFU) potential. We demonstrate that
cAMP regulation of hemogenic endothelium is depen-
dent on the cAMP-Epac signaling axis. Furthermore, we
propose that the cAMP-mediated increase in HSC-like
cells is in part coupled to cAMP-mediated mitigation
of oxidative burden and increasing hematopoietic cell
function.(F) Cell numbers obtained per well (per 1 3 104 seeded cells) after C
iments. Statistical analysis was performed using the t test. Significanc
not significant.
See also Figure S1.
694 Stem Cell Reports j Vol. 6 j 692–703 j May 10, 2016RESULTS
cAMP Induction Increases the Frequency of HSC-like
Cells Derived from hPSCs
To assess the role of cAMP signaling in human hemato-
poietic development, we differentiated hPSCs using our
previously described protocol (Ronn et al., 2015) whereby
mesoderm-biased embryoid bodies (EBs) were plated onto
the extracellular matrix allowing for adherence and expan-
sion of hemogenic endothelium, to generate hematopoi-
etic cells (Figure 1A). To elevate intracellular cAMP, we
applied a combination of forskolin and 3-isobutyl-1-meth-
ylxanthine (IBMX) from day 10. Forskolin specifically in-
creases intracellular cAMP levels by activating the catalytic
subunit of adenylyl cyclase (Seamon et al., 1981). IBMX
is a phosphodiesterase (PDE) inhibitor that specifically
prevents PDE-mediated dephosphorylation of cAMP to
AMP (Beavo et al., 1970). Thus, combining forskolin with
IBMX elevates intracellular cAMP by increasing cAMP
production and preventing its dephosphorylation. Fluores-
cence-activated cell sorting (FACS) analysis of the hPSC-
derived hematopoietic cells revealed that cAMP induc-
tion with forskolin + IBMX significantly increased the
numbers and frequency of our previously described HSC-
like cells (CD43+CD34+CD38CD90+CD45RA) (Figures
1B–1D).
To confirm that the upregulation of HSC-like cells was
specifically due to increased cAMP levels, we used two
different synthetic cAMP analogs, dibutyryl-cAMP and
8-Br-cAMP, to elevate intracellular cAMP during hPSC-to-
hematopoietic differentiation. Both cAMP analogs upregu-
lated the HSC-like phenotype (Figure S1A). Also, to rule
out any unspecific effects of forskolin we used 1,9-di-
deoxyforskolin, an inactive analog of forskolin that does
not activate adenylyl cyclase. We observed that HSC-like
phenotype was induced only with forskolin + IBMX, not
with 1,9-dideoxyforskolin + IBMX (Figure S1B), thus veri-
fying the specificity of forskolin-mediated effects through
cAMP.
Assessment of the differentiation capacity of hematopoi-
etic cells in a CFU assay showed an increase in granulocyte
CFU (CFU-G) and erythroid colonies, while the numbers
of macrophage CFU (CFU-M) were decreased (Figure 1E).
cAMP induction, although decreasing the numbers of
CFU-M colonies, significantly increased the total cell num-
ber resulting from the colony assay (Figure 1F) compared
with the non-induced control.FU assay. Data represent mean ± SEM of three independent exper-
e compared with the control setting: **p < 0.01, ***p < 0.001; n.s.,
Together, these data show that elevation of intracellular
cAMP upregulates hPSC-derived HSC-like surface pheno-
type, and also alters the distribution of colony types, favor-
ing mixed, granulocyte, and erythroid colonies at the
expense of macrophage colonies.
cAMP Signaling through the Epac Axis Is Required for
HSC-like Cell Generation from an Endothelial Cell
Intermediate
Intracellular cAMP downstream effectors, PKA and Epac,
influence cellular functions by regulating the activation
of various transcription factors and signaling molecules
(Cheng et al., 2008).We set out to elucidate themechanism
of cAMP-mediated upregulation of phenotypic HSC-like
cells during hPSC differentiation toward the hematopoietic
lineage. Epac inhibition abrogated the hematopoietic cell
generation efficiency as assessed by FACS measuring the
frequency of pan-hematopoietic marker CD43+ cells and
HSC-like cells (Figures 2A, 2B, and S2A). Inhibition of
PKA, on the other hand, had no negative effect on hemato-
poietic cells (Figures 2A, 2B, and S2A). The cell viability af-
ter PKA and Epac inhibition was similar to that of controls,
at 90%–95% (Figure S2B). We observed that inhibition
of Epac in the absence or presence of forskolin + IBMX
reduced the radial spreading of adherent endothelial-like
cells (emerging from the plated EBs) while PKA inhibition
did not have any effect (Figure 2C), the radial spread being
measured as indicated in Figure S2C. The reduced EB radial
spread after Epac inhibition was in accordance with a trend
in reduced total cell number at day 14 after Epac inhibition
(Figure S2D), suggesting that Epac inhibition affected cell
proliferation in a manner not associated with cell survival.
As bona fide hematopoietic cells are reported to emerge
from such endothelial spread (Eilken et al., 2009), we eval-
uated the effect of Epac inhibition on the frequency of
the previously described hemogenic endothelium pheno-
type cells (CD43CD34+CXCR4CD73VEcad+) (Ditadi
et al., 2015), whereby we applied the cAMP modulators
at days 6 and 8 and analyzed the cells at day 10 (schematic
regimen described in Figure S2E and Experimental Proce-
dures). Epac inhibition in the absence or presence of
forskolin + IBMX decreased the hemogenic endothelial
fraction (Figure 2D) without compromising the viability
of hemogenic endothelium (Figure S2F). Epac inhibition
also reduced the non-hemogenic endothelium (CD43
CD34+VEcad+) (Figure 2E) and arterial endothelium
(CD43CD34+CD90+CD73+CXCR4+) (Figure 2F). In con-
trast, the various endothelial cell types were insensitive to
PKA inhibition (Figures 2D–2F and S2A).
These results indicate that the cAMP-Epac axis plays a
pivotal role in the development of hematopoietic progeni-
tors and stem-like cells in hPSC differentiation cultures by
regulating hemogenic endothelial cell expansion.cAMP Induction Reduces Oxidative Stress and Induces
CXCR4 Upregulation in hPSC-Derived Hematopoietic
Cells
The deleterious effects of elevated ROS and its ensuing
oxidative damage on the function of mammalian HSCs
are well documented (Ito et al., 2006; Jang and Sharkis,
2007; Suda et al., 2011; Yahata et al., 2011). As cAMP induc-
tion decreased the prevalence of macrophages in our sys-
tem (Figure 1E), and as cAMP elevation coupled with PDE
inhibition has been reported to promote immune homeo-
stasis (Katakami et al., 1988; Sinha et al., 1995), we rational-
ized that cAMP induction with forskolin + IBMX might
mitigate the ROS burden in our hPSC-to-hematopoietic dif-
ferentiation system, thus protecting theHSC-like cells from
ROS-mediated effects mentioned above. Analysis of ROS
levels showed that cAMP induction decreased the ROS
levels in hPSC-derived hematopoietic cells compared
with the control setting (Figure 3A). cAMP induction along
with PDE inhibition (forskolin + IBMX), and protecting
endogenously available cAMP with PDE inhibition alone
(IBMX), significantly lowered the ROS levels in various he-
matopoietic phenotypes, including the HSC-like cells (Fig-
ure 3B), thus indicating reduced oxidative stress of these
hematopoietic cellular fractions.
The decreased ROS level after cAMP induction prompted
us to determine the status of genes that regulate the redox
state of cells and thus help to reduce the oxidative stress.
Transcriptional analysis of the redox-state-regulating genes
in hPSC-derived hematopoietic cells showed that nuclear
factor (erythroid-derived 2)-like 2 (NFE2L2) was upregu-
lated after cAMP induction with forskolin + IBMX (Fig-
ure 3C). NFE2L2 is a global regulator of the oxidative stress
response, as it binds to anti-oxidant response element in
the upstream promoter region of several anti-oxidative
genes and initiates their transcription (Itoh et al., 1997;
Tsai et al., 2013), thus initiating the mitigation of ROS-in-
duced oxidative stress in the cells. In our system, NFE2L2
upregulation after cAMP induction was in concert with
the upregulation of anti-oxidant genes, such as superoxide
dismutase (SOD1, SOD2), glutathione peroxidase (GPX2)
(18-fold increase), catalase (CAT), and glutathione S-reduc-
tase (GSR) (Figure 3C).
Stress conditions activate p38 mitogen-activated protein
kinases (p38MAPK) (Raingeaud et al., 1995). ROS/stress-
mediated p38MAPK activation leads to HSC self-renewal
defects and reduced HSC long-term repopulation potential
(Ito et al., 2006; Jang and Sharkis, 2007). Thus we analyzed
the levels of stress-activated p38 pathway components P38-
MAPKa, d, and g and found that cAMP induction generally
reduced the levels of these p38MAPK isoforms (Figure 3D),
indicative of reduced stress. As elevated ROS levels have
been shown to induce differentiation of hematopoietic
progenitors toward mature lineages (Jang and Sharkis,Stem Cell Reports j Vol. 6 j 692–703 j May 10, 2016 695
A
H
SC
-li
ke
 
(fr
eq
ue
nc
y i
n v
iab
le)
1
0
1.5
2
2.5
0.5
*
**
**
**
n.s.
B
Co
nt
ro
l
FS
K+
IB
M
X
PK
Ai
PK
Ai
 +
 
FS
K+
IB
M
X
Ep
ac
i
Ep
ac
i +
 
FS
K+
IB
M
X
FSC-H
CD
43
CD34 FSC-H
12%
48%
9%
Blood Progenitors HSC-like
10%
32%
9%
1.2%
0%
0%
34%
20%
78%
27%
26%
88%
4.3%
3%
0%
Control
FSK + IBMX
PKAi
PKAi + FSK + IBMX
Epaci
Epaci + FSK + IBMX
C
********
n.s.
n.s.
n.s.
Em
br
yo
id
 b
od
y 
sp
re
ad
 (  
m) µ 400
600
200
0
D
H
em
og
en
ic 
e
n
do
th
el
iu
m
 (fo
ld)
1
0
1.5
0.5
*
**
n.s.
n.s.
n.s.
FE
Ar
te
ria
l
e
n
do
th
el
iu
m
 (fo
ld)
n.s.
n.s.
n.s.
**
**
0
0.5
1
1.5
2
N
on
-h
em
og
en
ic
e
n
do
th
el
iu
m
 (fo
ld)
0
0.5
1
1.5
n.s.
n.s.
n.s.
*
**
FS
C-
H
FS
C-
H
FS
C-
H
FS
C-
H
FS
C-
H
FS
C-
H
CD
90
CD
90
CD
90
CD
90
CD
90
CD
90
Figure 2. cAMP-Mediated HSC-like Upregulation Occurs through the cAMP-Epac Axis
(A) Quantification of HSC-like frequency in viable (at day 14) after PKA or Epac inhibition. Data represent mean ± SEM of three inde-
pendent experiments. Statistical analysis was performed using the t test. *p < 0.05, **p < 0.01; n.s., not significant.
(B) Representative flow cytometry plots (biexponential axis) showing the CD43+ blood cells and HSC-like cells (day 14) generated after
forskolin + IBMX-mediated cAMP induction and PKA or Epac inhibition (PKAi, Epaci), with or without forskolin + IBMX.
(C) Quantification of radial spread of EBs (distance between center of EB and outer edge of the cellular spread, day 13). Data represent
mean ± SEM of 100 EBs from three independent experiments. Statistical analysis was performed using the t test. ****p < 0.0001; n.s., not
significant.
(D) Analysis of hemogenic endothelial (CD43CD34+CXCR4CD73VEcad+) phenotype (day 10), after cAMP induction and PKA or Epac
inhibition (PKAi, Epaci) with or without cAMP induction. Data represent mean ± SEM of three independent experiments; mean fold change
respective to control is shown. Statistical analysis was performed using the t test. *p < 0.05, **p < 0.01; n.s., not significant.
(E) Analysis of general (non-hemogenic) endothelium (CD43CD34+VEcad+) at day 10, after cAMP induction and PKA or Epac inhibition
(PKAi, Epaci) with or without cAMP induction. Data represent mean ± SEM of three independent experiments; mean fold change respective
to control is shown. Statistical analysis was performed using the t test. *p < 0.05, **p < 0.01; n.s., not significant.
(F) Analysis of arterial endothelium (CD43CD34+CD90+CD73+CXCR4+) at day 10, after cAMP induction and PKA or Epac inhibition (PKAi,
Epaci) with or without cAMP induction. Data represent mean ± SEM of three independent experiments; mean fold change respective to
control is shown. Statistical analysis was performed using the t test. **p < 0.01; n.s., not significant. For (D)–(F) the analysis was done at
day 10, as the hemogenic endothelium is less abundant after this time point.
See also Figure S2.2007; Suda et al., 2011), we analyzed the abundance of
mature hematopoietic cells (CD43+CD34CD38+) in our
differentiation assay. cAMP induction reduced the preva-
lence of mature hematopoietic progenitors (Figure 3E),
indicating the role of cAMP in preventing cell maturation
and agreeing to the reduced ROS levels after cAMP induc-696 Stem Cell Reports j Vol. 6 j 692–703 j May 10, 2016tion (Figures 3A and 3B). Together, these data indicate
that cAMP induction with forskolin + IBMX upregu-
lated anti-oxidant defense mechanisms and downregu-
lated stress-activated genes, thus creating a redox balance
in our system that is favorable for hematopoietic progeni-
tor and stem-like cell maintenance.
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Figure 3. cAMP Induction Reduces Oxida-
tive Stress and Induces CXCR4 in hPSC-
Derived Hematopoietic Cells
(A) Flow cytometry analysis for detection
of reactive oxygen species (ROS) in differ-
entiated hPSC-to-hematopoietic cells at day
14 of differentiation. Representative flow
cytometry plots (biexponential x axis) show
ROS levels in the hematopoietic surface
phenotypes. FMO control, fluorescence-
minus-one (staining control).
(B) Quantification of geometric mean fluo-
rescence intensity (gMFI) of CellROX dye as
indicated in (A). Data represent mean ± SEM
of three independent experiments. Statis-
tical analysis was performed using the t test.
Significance compared with the control
setting: *p < 0.05, **p < 0.01; n.s., not
significant.
(C and D) qRT-PCR expression analysis of
the indicated redox-state-regulating genes
(C) and p38MAPK-related genes (D) in
PSC-derived hematopoietic cells. Relative
expression of each gene to housekeeping
gene ACTB (b-ACTIN) was calculated, and
mean fold change respective to control
condition (set at 1) is shown. Data repre-
sent mean ± SEM of three independent
experiments. Statistical analysis was per-
formed using the t test. Significance
comparedwith the control setting: *p<0.05,
**p < 0.01; n.s., not significant.
(E) Analysis of mature hematopoietic pro-
genitors (CD43+CD34CD38+) after cAMP in-
duction (day 14). Data representmean± SEM
of three independent experiments. Statisti-
cal analysis was performed using the t test.
Significance compared with the control
setting: *p < 0.05; n.s., not significant.
(F) Expression of CXCR4 across indicated
hematopoietic surface phenotypes. Data
represent mean ± SEM of three independent
experiments. Statistical analysis was per-
formed using the t test. Significance compared with the control setting: *p < 0.05, **p < 0.01, ***p < 0.001; n.s., not significant.
(G) Expression of CXCR4 in HSC-like surface phenotype (ROSlow fraction). Data represent mean ± SEM of three independent experiments.
Statistical analysis was performed using the t test. Significance compared with the control setting: ***p < 0.001, n.s., not significant.
See also Figure S3.The chemokine receptor CXCR4 is pivotal for retaining
quiescent HSCs in the BMniche, as well as for HSC homing
to BM (Lai et al., 2014; Nie et al., 2008; Peled et al., 1999).
Given that cAMP and PGE2 treatment has been shown to
increase CXCR4 expression in adult HSCs/human cord
blood CD34+ cells (Goessling et al., 2011; Goichberg et al.,
2006; Hoggatt et al., 2009), we analyzed CXCR4 levels
in our hPSC-derived hematopoietic cells following cAMP
induction. Analysis of CXCR4 expression revealed thatcAMP induction with forskolin + IBMX enhanced CXCR4
expression across various hematopoietic surface pheno-
types, including the HSC-like fraction (Figure 3F). Impor-
tantly, CXCR4 expression was enhanced in the ROSlow
HSC-like surface phenotype upon treatment with forsko-
lin + IBMX (Figure 3G). We investigated whether cAMP-
mediated CXCR4 modulation was regulated through
PKA or Epac. cAMP-induced upregulation of CXCR4 was
insensitive to inhibition of PKA, indicating that CXCR4Stem Cell Reports j Vol. 6 j 692–703 j May 10, 2016 697
regulation does not depend on PKA. On the contrary,
Epac inhibition reduced CXCR4 expression, indicating
that CXCR4 regulation was mediated by the cAMP-Epac
axis (Figure S3). Our data showing that PKA does not regu-
late CXCR4 expression agree with a previous finding where
cAMP-mediated CXCR4 elevation (in human mobilized
peripheral bloodCD34+ cells)was insensitive toPKA inhibi-
tion (Goichberg et al., 2006).
Together, these findings show that cAMP induction
reduced the oxidative burden by creating a redox-state bal-
ance in hPSC-derived hematopoietic cells and upregulated
CXCR4 in the HSC-like cells, both essential for HSC
functionality.DISCUSSION
Using an hPSC differentiation system to model human he-
matopoietic cell emergence and development, our findings
suggest that cAMP and signaling through its Epac axis is an
important factor for the generation of hemogenic endothe-
lium, from which the first hematopoietic cells arise. Thus
cAMP is a crucial second messenger molecule regulating
the in vitro hPSC-derived HSC-like cells. Interestingly,
cAMP induction upregulated the frequency of HSC-like
cells in the differentiation cultures and also mitigated
oxidative stress, created redox-state balance, and enhanced
CXCR4 expression in hPSC-derived hematopoietic cells,
thus suggesting multiple independent functions of cAMP
signaling in endothelial and hematopoietic cells. Because
of the importance of low ROS levels in maintaining repo-
pulating human HSCs (Jang and Sharkis, 2007; Yahata
et al., 2011), the identification of cAMP-mediated ROS
reduction inhPSCdifferentiation systems provides amech-
anism for how ROS can be regulated in in vitro systems to
better mimic in vivo HSC development. We speculate that
the presence of mature immune cells elevates ROS activity
in our differentiation system. The reduction inmature cells
and decreased macrophage numbers following cAMP in-
duction agrees with cAMP-mediated redox-state balance,
leading to decreased ROS levels. ROS reduction was in
concert with the increase of anti-oxidant gene response,
decrease in the p38 stress pathway components, and
reduced prevalence ofmature hematopoietic cells. In terms
of cAMP-mediated ROS reduction and reduction of mature
progenitors, the reduced abundance of differentiated cells
could in part result in decreased ROS, or, alternatively,
low ROS levels could be playing a role to reduce differenti-
ation, either way both benefiting the system for increasing
the prevalence of HSC-like cells.
Thus,benefitsof cAMP, in termsofdecreasedROS/p38and
maintenance of redox balance together, created a better
environment for the HSC-like cells, presumably helping698 Stem Cell Reports j Vol. 6 j 692–703 j May 10, 2016their survival, preventing premature senescence, andmain-
taining their functionality, as has been shown for adult
HSCs. cAMP induction reduced p38 signaling, which is
beneficial for the maintenance of human hematopoietic
stem and progenitor cells (Baudet et al., 2012; Zou et al.,
2012). The ability of cAMP to regulate inflammation and
ROS has been shown previously, either by reducing pro-
inflammation cytokines and enhancing the T helper 2 re-
sponses in inflamed human blood cells (Harris et al., 2002;
Snijdewint et al., 1993; Yoshimura et al., 1997) or via
suppressing inflammation/ROS through the cAMP-Epac
axis (Remans et al., 2004; Xu et al., 2008). In our assay,
cAMP-mediated ROS/p38 reduction, increased anti-oxidant
response, and reduced differentiation could inpart be attrib-
uted to these inflammation-regulating actions of cAMP.
We speculate that ROS reduction has an important, but
not exclusive, regulatory role in the cAMP-mediated main-
tenance of HSC-like cells. Moreover, cAMP-mediated ROS/
p38 reduction and increased CXCR4 receptor expression
provide a correlational benefit to HSC-like cells, as low
ROS levels specifically increased the CXCR4high HSC-like
cells. These findings suggest that cAMP induction imparts
important functional properties to the derived hematopoi-
etic cells, as low oxidative stress (Ito et al., 2006; Jang and
Sharkis, 2007; Yahata et al., 2011) and high CXCR4 expres-
sion (Nie et al., 2008; Peled et al., 1999) are properties of
HSCs with long-term transplantation potential.
Multiple factors, through binding to GPCRs, orchestrate
the regulation of cAMP levels in a cell- and context-depen-
dent manner, an effect that is most likely to be preserved
during embryonic hematopoietic emergence and develop-
ment (Diaz et al., 2015; Goessling et al., 2011; Hoggatt
et al., 2009; Jing et al., 2015; Kim et al., 2015; Li et al.,
2014; North et al., 2007). Thus, the regulatory networks
involved in cAMP-mediated regulation of hematopoietic
development are likely to be multifactorial and intercon-
nected. Detailed dissection of such signals is therefore
required to elucidate the signaling networks that trigger
cAMP-mediated benefits to hematopoietic cells.
Our findings on thepro-hematopoietic effects of cAMPon
hPSC-derived hematopoietic cell specification are in agree-
ment with reports describing the pivotal role of cAMP
signaling in promoting and enhancingmouse and zebrafish
hematopoietic development (Diaz et al., 2015; Jing et al.,
2015; Kim et al., 2015), as well as human CD34+ cord
blood/mobilized peripheral blood survival and engraftment
(Goessling et al., 2011; Li et al., 2014). These studies demon-
strated that cAMP activation via fluid shear stress in the
murine system(Diaz et al., 2015;Kimetal., 2015), adenosine
signaling in the zebrafish hematopoietic system (Jing et al.,
2015), and PGE2 in human CD34+ cells (Goessling et al.,
2011; Li et al., 2014), instructs hematopoietic specification,
mediated through the cAMP-PKA axis. In our in vitromodel
of human hematopoietic development, using an hPSC dif-
ferentiation system, we show that by inhibiting the down-
stream effectors of cAMP signaling, PKA and Epac, only
Epac signaling is required for hematopoietic development,
notwithstanding that apart from affecting the underlying
endothelium, Epac inhibition appears to affect the newly
formed HSC-like cells. As experimental modulation of
cAMP signaling to instruct HSC fate from hPSCs has not
yet been achieved (Traver, 2015), our finding describing
the pro-hematopoietic benefits of cAMP on hPSC-derived
human hematopoietic cells is a key step toward refining
modalities of human HSC generation using cAMP. Toward
understanding the in vivo emergence and development
of human HSCs, our findings on human PSC-derived he-
matopoietic cell generation necessitate further evaluation
of cAMP and its signaling components during definitive hu-
man hematopoiesis, i.e., either directly in human fetuses or
by developing culture systems to propagate human AGM
region in vitro, notwithstanding the ethical and technical
challenges related to this pursuit.
cAMP-mediated Epac upregulation has been reported
to reorganize cortical actin, enhance vascular endothelial
cadherin-mediated cell adhesion, and induce integrin-
mediated cell adhesion, leading to decreased endothelial
cell permeability and enhanced endothelial barrier func-
tion (Cullere et al., 2005; Fukuhara et al., 2005; Rangarajan
et al., 2003). Developmentally, in the early embryo he-
matopoietic cells (including cells with the potential to
form HSCs) emerge from hemogenic endothelium in the
AGM region through EHT (Chen et al., 2009; Zovein
et al., 2008). From our Epac inhibition experiments, we
demonstrate the critical role of Epac signaling in modu-
lating hPSC-derived hemogenic endothelium and HSC-
like cells. Epac being one of the downstream effectors of
cAMP that regulates endothelial cell-cell adhesion, perme-
ability, and barrier functions may suggest a link between
endothelial cell mechanobiology and hemogenic endothe-
lial cell function. However, due to the inability to currently
evaluate pure populations of human endothelial cells with
hematopoietic potential, confirmation of Epac’s role,
whether specifying hematopoietic function at the hemo-
genic endothelium (HE) cell stage, or acting indirectly on
HE via an upstream cell intermediate, is still necessary.
Collectively, our findings suggest that cAMP regulates
the generation and function of human HSCs via multiple
separate mechanisms in both the endothelial and hemato-
poietic cell fractions. By demonstrating the role of cAMP-
Epac axis in hematopoietic cells and HSC-like cells using
an in vitro human development model, our study provides
insights into understanding the previously unknown role
of the cAMP-signaling component in human hematopoi-
etic development. Taken together, these findings advance
our current understanding of human hematopoietic devel-opmental mechanisms toward the development of trans-
plantable hematopoietic cells for therapeutic purposes.EXPERIMENTAL PROCEDURES
Human Pluripotent Stem Cell Culture
Human iPSC line RB9-CB1 derived from cord blood endothelial
cells (Ronn et al., 2015; Woods et al., 2011) was cultured on irradi-
ated mouse embryonic fibroblasts in DMEM/Nutrient Mixture
F-12 (DMEM/F12) supplemented with 20% KnockOut-serum
replacement (KO-SR), 2 mM L-glutamine, 0.1 mM non-essential
amino acids, 0.1mM2-mercaptoethanol, and 10 ng/ml basic fibro-
blast growth factor, all from Thermo Fisher Scientific. The cells
were incubated in a humidified incubator at 37C and 5% CO2.Embryoid Body Formation and Hematopoietic
Differentiation
EBs were prepared after incubating the pluripotent stem cell col-
onies with 2 mg/ml Dispase (Thermo Fischer Scientific), followed
by gentle pipetting. The detached colonies were washed twice
with 20% KO-SR containing DMEM/F12, before plating in ultra-
low-adherence suspension culture dishes (Corning Life Sciences)
to form EBs for 8 days. During suspension culture, the MesoTotal
HPC/HSC Differentiation System (Primorigen Biosciences) was
used to specify the EBs toward mesoderm commitment. At day 8,
EBs were plated on 0.08 mg/mm2 Matrigel (BD Biosciences), and
further differentiation toward hematopoietic cells was carried out
until day 14 in MesoTotal medium. Application of fresh me-
dium and cAMP induction with 10 mM forskolin (Stemgent) and
500 mM IBMX (3-isobutyl-1-methylxanthine; Santa Cruz Biotech-
nology) was carried out at days 10 and 12 of differentiation. For in-
hibition of PKA and Epac, 50 mM PKA inhibitor (Rp-8-CPT-cAMPS)
(Staples et al., 2001; Yu et al., 2014) and 20 mM Epac inhibitor
(ESI-09) (Almahariq et al., 2013; Zhu et al., 2015) (both from
BioLog Life Science Institute) were used (20 min pre-treatment
followed by cAMP induction) on days 10 and 12 of differentiation,
and the cells were analyzed on day 14. These inhibitors occupy
cAMP-binding domains of their respective receptor (PKA or
Epac), thus blocking further cAMP binding and inhibiting the
functions of PKA or Epac. For analysis of hemogenic endothelium,
PKA and Epac were inhibited on day 6 (EB stage) and day 8
(adherent stage) and the cells were analyzed on day 10 (schematic
regimen, Figure S2E). We selected day 10 to analyze hemogenic
endothelium, as this population is less abundant after day 12
(data not shown). For measurement of EB radial spread, the dis-
tance between center of an EB and outer edge of its cellular spread
was analyzed on day 13 of differentiation (Figure S2C) using
ImageJ (developed at the NIH).Colony Formation Assay
After 14-day hPSC-to-hematopoietic differentiation, the differenti-
ated hematopoietic cells were plated (1 3 104 cells/9.5 cm2) in
Methocult H4230 (STEMCELL Technologies) supplemented with
2.5 mg/ml human Stem Cell Factor, 2.5 mg/ml human inter-
leukin-3, 5 mg/ml human granulocyte-macrophage colony-stimu-
lating factor, and 500 U/ml erythropoietin, all recombinantStem Cell Reports j Vol. 6 j 692–703 j May 10, 2016 699
human cytokines from PeproTech. For cells treated with forsko-
lin or IBMX, or a combination of both, similar treatment was
continued in the CFU assay (chemicals added to the CFU medium
on the first day of CFU assay), and after 12 days hematopoietic
colonies were scored microscopically to evaluate various CFU
phenotypes.
Flow Cytometry
For analysis of surface markers, cells harvested using TrypLE Select
(Thermo Fisher Scientific) were labeledwith primary antibodies for
30 min at 4C. The following fluorophore-conjugated antibodies
were used: CD43-FITC (catalog #555475, clone 1G10), CD45RA-
V450 (#560363, clone HI100), CD73-PE (#550257, clone AD2),
anti-VE-cadherin-Percp-Cy5.5 (#561566, clone 55-7H1) (all from
BD Biosciences), and CD34-PE.Cy7 (#343515, clone 581), CD38-
APC (#303509, clone HIT2), CD90-PE (#328110, clone 5 3 1010),
and CXCR4-BV421 (#306517, clone 12G5) (all from BioLegend).
After incubationwith the antibodies for 30min, cells werewashed,
resuspended in 2% fetal bovine serum (Thermo Fischer Scientific)
containing PBS, and acquired with BD FACSCanto (BD Biosci-
ences). To detect oxidative stress, we used CellROX Deep Red
(#C10422, Life Technologies) according to the manufacturer’s in-
structions. For live/dead cell discrimination, 7-amino-actinomycin
D (BD Biosciences) was applied to the cells before acquisition. Dot
plots were derived from gated events based on size and scatter char-
acteristics and doublet-exclusion, fluorescence-minus-one con-
trols were used to identify gating boundaries. Acquired events
were analyzed using FlowJo software.
RNA Isolation and qRT-PCR
Total RNA from cells was extracted using an RNeasyMicro Kit (Qia-
gen) and 500 ng of total RNA was reverse transcribed to cDNA
using SuperScript III reverse transcriptase (Life Technologies) ac-
cording to the manufacturer’s instructions. qPCR was performed
with gene-specific primers (Table S1) (Dannenmann et al., 2015)
using SYBR GreenER qPCR SuperMix (Life Technologies) in a
7900HT Fast Real-Time PCR system (Life Technologies), and the
relative expression to housekeeping gene b-ACTIN was analyzed
by comparative CT method (Livak and Schmittgen, 2001).
Statistical Analysis
Statistical analysiswas performedusingGraphPad Prism (GraphPad
Software). Quantitative data represent mean ± SEM, unless other-
wise stated, and n represents the number of biological replicates.
For statistical evaluation, Student’s t test (two-tailed)wasused, statis-
tical significance in the figures being indicated by *p < 0.05, **p <
0.01, ***p < 0.001, and ****p < 0.0001.
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